ISLET Act
Introduced March 19, 2026 · Last action March 19, 2026
Plain English Summary
This bill reclassifies human cadaveric islets (insulin-producing cells harvested from deceased donors' pancreases) as organs eligible for transplantation under the National Organ Transplant Act, rather than treating them as drugs, biological products, or tissue-based products. It directs the Secretary of Health and Human Services to update federal regulations within one year to implement this reclassification and exempt islets from drug, biological product, and tissue regulations.
Who benefits
Type 1 and Type 2 diabetes patients eligible for islet transplantation; transplant surgeons and endocrinologists performing islet transplants; academic medical centers and hospitals with islet transplant programs; organ procurement organizations (OPOs) involved in islet recovery and distribution; islet processing and isolation facilities; companies developing islet preservation and transplant technologies.
Who pays / loses
Pharmaceutical and biotechnology companies that currently develop islet-derived therapies or cellular products under the biological product/drug regulatory framework (who will lose FDA oversight pathways for certain islet-based treatments); patients who might have benefited from islet therapies as pharmaceutical products with FDA-regulated quality controls; entities currently extracting value from islets under tissue product regulations.
Funding & Lobbying Interests
Transplant medicine companies and islet processing facilities (such as Cell Transplantation Inc., Lund University Diabetes Center partners, and commercial islet isolation providers) have a financial interest in reclassifying islets as organs, as this streamlines regulatory pathways and increases demand for their services. Academic transplant programs and organ procurement organizations also benefit from expanded islet availability. Diabetes research organizations (American Diabetes Association, JDRF) may support expanded islet transplant access. The bill's sponsors (Reps. Norman and Bacon) are from South Carolina and Nebraska respectively; no specific donor finance data was provided in the submitted materials.
Political Impact
Affected Groups
Approximately 8.5 million Americans with type 1 diabetes and 37.3 million with type 2 diabetes, though only a small subset are candidates for islet transplantation (estimated hundreds to low thousands annually in the U.S.). Transplant-eligible patients with brittle diabetes or severe hypoglycemia unawareness face the highest material benefit. Deceased organ donors and their families (expanded donation opportunity without additional medical intervention). Healthcare systems operating transplant centers in urban and academic medical centers benefit; rural areas with limited transplant infrastructure do not.
Political Subtext
Proponents argue this bill removes regulatory barriers that slow islet transplantation for diabetic patients, allowing life-saving treatments to reach patients faster without pharmaceutical-grade bureaucratic delays. They frame islets as organs, not drugs, positioning them alongside kidney and liver transplantation. Critics may argue that reclassifying islets as organs removes FDA oversight mechanisms designed to ensure product safety, purity, and efficacy—particularly given that islet isolation and processing involve multiple steps where contamination or cell death can occur. They may contend that removing drug/biological product regulation could lower safety standards. Non-partisan evidence from transplant medicine consensus is that islet transplantation is effective for select patients with severe type 1 diabetes, but adoption remains limited by cold preservation time, islet quality variability, and immunosuppression burden. The CBO and GAO have not issued formal assessments on this specific bill.
Real-World Stakes
If this passes, islet transplantation will be regulated as organ transplantation under the Organ Procurement and Transplantation Network (OPTN) and UNOS allocation rules, rather than as a pharmaceutical product requiring FDA premarket approval. This could accelerate islet availability and reduce time-to-transplant by eliminating IND (Investigational New Drug) applications and Phase II/III trials for routine islet products. Historical precedent: When kidney and heart transplantation were designated as organs in the 1980s, oversight shifted from FDA to OPTN/UNOS, resulting in rapid expansion of transplant programs but also variability in center quality and patient outcomes. The practical effect: patients in centers with strong islet programs (typically large academic medical centers) could access transplantation faster; patients in rural or underserved areas remain dependent on geographic proximity to specialized transplant centers. Reclassification does not create new islets—it redistributes existing deceased-donor supply under a different regulatory framework. No CBO cost estimate or civil rights impact assessment was included in the bill text.
What's Inside This Bill
Non-obvious provisions not apparent from the headline summary.
Retroactive Exemption from FDA Drug/Biologic Oversight
By reclassifying islets as organs rather than drugs or biologics, the bill exempts them from FDA pre-market approval, manufacturing standards (cGMP), and post-market surveillance requirements that currently apply to all cellular therapeutics and biological products.
AffectsPatients receiving islet transplants would lose FDA safety monitoring, manufacturing consistency standards, and adverse event tracking that apply to other cellular therapies. Manufacturers gain reduced regulatory burden but with less oversight of product quality and safety.
Preemption of State-Level Islet Regulations
Treating islets as organs under the National Organ Transplant Act preempts state laws regulating tissue and cellular products, which many states currently oversee through tissue banking and cellular therapy licensing.
AffectsStates lose authority to impose their own islet quality, safety, or tracking standards, and tissue banking facilities in states with stricter requirements may face reduced regulatory authority over islet collection and storage.
One-Year Regulatory Rewrite Without Explicit Safety Requirements
The bill requires HHS to update regulations within one year but does not specify that safety, efficacy, or quality standards must be maintained in the new framework, only that islets be exempted from existing drug/biologic/tissue regulations.
AffectsDuring and after the one-year rulemaking period, there is ambiguity about what safety standards will actually govern islet transplantation, potentially creating a regulatory gap where islets operate under less stringent oversight than they do currently.
Allocation Priority Under Organ Transplant Rules
By reclassifying islets as organs, they become subject to UNOS allocation protocols designed for scarce organs (hearts, livers, kidneys), potentially shifting priority from current criteria used for tissue-based islet allocation.
AffectsPatients currently in islet transplant queues may see changes in allocation priority; centers with different patient populations or geographic areas may gain or lose access to islets based on organ-transplant allocation algorithms rather than tissue-based allocation.
Sponsor
Co-sponsors (6)
RRep. Gill, Brandon [R-TX-26]RRep. Bresnahan, Robert [R-PA-8]RRep. Mann, Tracey [R-KS-1]RRep. Garbarino, Andrew R. [R-NY-2]RRep. Bacon, Don [R-NE-2]RRep. LaLota, Nick [R-NY-1]
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
Top contributing industries
Other$117,357.52
Finance$6,230
Agriculture$3,550
Law$2,000
Defense$1,500
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.